Following longest known chronic SARS-CoV-2 infection of 613 days, experts highlight the risk of development of novel potentially immune-evasive SARS-CoV-2 variants due to persistent infections in immunocompromised patients
Authors propose enhancing awareness of risks, close genomic surveillance and early diagnostic tests for symptomatic contacts as part of clinical management of these patients. *Please mention the ESCMID Global Congress (formerly ECCMID) Barcelona, 27-30 April) if using this material* New research to be presented at next week’s ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) highlights the risk of new immune-evasive SARS-CoV-2 variants emerging in immunocompromised patients. The report is by PhD candidate Magda Vergouwe, Centre for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam, Netherlands, and colleagues.